drugset / Trial / NCT05368805
Fruquintinib DDI Study With P-gp and BCRP Substrates
Non-randomizedParallel-groupOpen-labelOther
Summary
Fruquintinib DDI Study with P-gp and BCRP Substrates
Timeline
- Start
- 2022-03-02
- Primary completion
- 2022-04-22
- Completion
- 2022-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 150 mg | Oral |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | Rosuvastatin | Small molecule | 10 mg | Oral |